X @Forbes

Funding & Investment - Illimis Therapeutics secured 58 billion won (approximately $42 million) in funding [1] - The funding aims to support research into Alzheimer's disease treatments [1] - The funding will also facilitate expansion into immune diseases [1] Company Focus - Illimis Therapeutics is based in Seoul [1] - The company is focused on developing treatments for Alzheimer's disease [1] - The company is expanding its research focus to include immune diseases [1]